merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>The risks outweighed the potential for a slight benefit</answer>

<question_number>2</question_number>
<answer>It's slowing progress and might discourage patients from participating in trials for treatments that could be better</answer>

<question_number>3</question_number>
<answer>There's no correlation in any of their studies between the removal of amyloid plaques and the clinical response in individual subjects</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>The higher price reflects the expectation that patients can stop Kisunla after their plaques are cleared</answer>

<question_number>6</question_number>
<answer>Might discourage patients from participating in trials for treatments that could be better</answer>

<question_number>7</question_number>
<answer>Patients can stop the drug after it clears amyloid and it's given monthly rather than every two weeks</answer>

<question_number>8</question_number>
<answer>Amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels</answer>